IN8bio has a new chief scientist, and the company’s own newsletter is acknowledging that this week’s update is a modest one. The STAT+ newsletter “Up and down the ladder: The latest comings and goings” typically tracks who moves where across biotech. This week, it has exactly one name to put on its board: Oxana Polyakova, who joined IN8bio as senior vice president of research and development. She previously served as chief scientific officer at LAVA Therapeutics.
The newsletter asks readers to send in their own changes, promising to share them with others. “Don’t be shy,” it says. “Everyone wants to know who is coming and going.”
The One Named Hire
Polyakova’s appointment is the whole story. She arrives at IN8bio after her time at LAVA Therapeutics, where she held the top scientific post. The newsletter describes her role at IN8bio as senior vice president of research and development.
There is no detail on what IN8bio does, what LAVA Therapeutics does, or what Polyakova’s new responsibilities will be. The focus is the change itself.
The Joke About the Veep
The newsletter’s light-hearted line about a dull R&D senior veep reads as a kind of self-awareness. It is a small joke about the thinness of the week’s actual content.
The line works because it acknowledges the gap between the newsletter’s promise and its delivery. There is only one veep to talk about, and the newsletter makes a point of it.
What We Know About Polyakova
Polyakova’s background is the only substantive information in the piece. She served as chief scientific officer at LAVA Therapeutics before joining IN8bio as senior vice president of research and development.
That is the full extent of the record. The newsletter does not describe her prior work, her area of expertise, or her role at LAVA beyond the title.
Here is what the newsletter tells us about Polyakova:
- Her new position: senior vice president of research and development at IN8bio
- Her previous role: chief scientific officer at LAVA Therapeutics
- Her move: from LAVA Therapeutics to IN8bio
The Newsletter’s Pitch
The newsletter’s core pitch is straightforward. It asks companies to share their changes, promising to find a home for them. The implication is that readers want to know who is moving where, even if the newsletter itself cannot always deliver a full round of names.
The request stands alone, asking for more than the newsletter can currently provide.
A Round of One
The newsletter’s featured item this week is a single hire. The request to readers stands alongside it, asking for more than the newsletter can currently provide.
| Item | Detail |
|---|---|
| New hire | Oxana Polyakova, senior vice president of research and development at IN8bio |
| Previous role | Chief scientific officer at LAVA Therapeutics |
| Source | STAT+ newsletter “Up and down the ladder: The latest comings and goings” |
What This Means for Readers
For STAT+ subscribers, this week’s newsletter delivers one piece of news and a request for more. The subscriber base gets the Polyakova hire, the joke about the dull veep, and the invitation to contribute.
The newsletter’s own admission of its thinness is part of the appeal. It is a newsletter that knows it is small and jokes about it.
The Bottom Line
The newsletter’s featured item this week is a single hire. The request to readers stands alongside it, asking for more than the newsletter can currently provide.
The newsletter’s own admission of its thinness is part of the appeal. It is a newsletter that knows it is small and jokes about it.
The paper’s honest reaction to this story is amusement: a newsletter devoted to staff changes itself has only one named hire to report, and it jokes about its own lack of depth. That is the whole of it.
Source material: “STAT+: Up and down the ladder: The latest comings and goings,” STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.